Company Filing History:
Years Active: 2002
Title: The Innovations of John R. Glowa
Introduction
John R. Glowa is a notable inventor based in Shreveport, Louisiana. He has made significant contributions to the field of pharmaceuticals, particularly in the development of sustained-release derivatives. His work focuses on enhancing the efficacy of treatments related to dopamine transporters.
Latest Patents
John R. Glowa holds a patent for "Sustained-release derivatives of hydroxylated analogs of substituted 1-[2[bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines and their use." This invention provides sustained-release derivatives that can effectively bind to the dopamine transporter. The goal is to achieve desired effects, such as antagonism of dopamine reuptake inhibitors like cocaine, or dopamine releasers and norepinephrine and/or serotonin reuptake inhibitors like methamphetamine. He has 1 patent to his name.
Career Highlights
Glowa is affiliated with the National Institutes of Health, a component of the U.S. Department of Health & Human Services. His work at this prestigious institution has allowed him to contribute to important research in the pharmaceutical field.
Collaborations
Throughout his career, John R. Glowa has collaborated with esteemed colleagues, including Richard B. Rothman and Kenner C. Rice. These partnerships have furthered his research and innovation in the field.
Conclusion
John R. Glowa's contributions to pharmaceutical innovations demonstrate his commitment to advancing medical science. His work on sustained-release derivatives showcases the potential for new treatments in addressing critical health issues.